Home » Stocks » LEGN

Legend Biotech Corporation (LEGN)

Stock Price: $31.02 USD 0.67 (2.21%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 4.14B
Revenue (ttm) 75.68M
Net Income (ttm) -303.48M
Shares Out 135.36M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $31.02
Previous Close $30.35
Change ($) 0.67
Change (%) 2.21%
Day's Open 30.35
Day's Range 30.35 - 31.25
Day's Volume 492,016
52-Week Range 23.41 - 43.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #ASCO21--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development ...

1 day ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

1 week ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #biotech--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development...

1 month ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)-- #LegendBiotech--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development o...

2 months ago - Business Wire

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LLY, NKTX, RHHBY, RNA
2 months ago - GuruFocus

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

3 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)-- #LegendBiotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development...

4 months ago - Business Wire

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing ant...

Other stocks mentioned: ABBV, ADCT, ALLO, BNTX, YMAB
4 months ago - Seeking Alpha

SOMERSET, N.J.--(BUSINESS WIRE)-- #JPM2021--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of no...

4 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)-- #biotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of no...

4 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)-- #LYMSM--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nove...

4 months ago - Business Wire

Targeting BCMA is all the rage, but who will come out on top?

Other stocks mentioned: BLUE, BMY, JNJ, REGN
5 months ago - The Motley Fool

Drugmakers are targeting B-cell maturation antigen in different ways.

Other stocks mentioned: BLUE, BMY, JNJ, REGN
5 months ago - The Motley Fool

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)-- #ASH20--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, December 7 at 7...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and development...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

6 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell ther...

6 months ago - Business Wire

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Legend Bio To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - ...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 22, 2020) - Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend" or "the Company") (NASDAQ: LE...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 8, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Legen...

7 months ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $LEGN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

7 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell ther...

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - September 26, 2020) -  Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Leg...

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - September 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of L...

7 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Legend Biotech Corporation (NASDAQ: L...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #CLASSACTION--Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN)

7 months ago - Business Wire

Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN) on behalf of inv...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #LEGN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation

7 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $LEGN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Legend Biotech C...

7 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN) complied with federal securities laws. On September ...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #LEGN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation.

7 months ago - Business Wire

A customs investigation is sending this Chinese biotech stock lower today.

7 months ago - The Motley Fool

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell t...

7 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell ther...

8 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell ther...

8 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended ...

9 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell ther...

9 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech (NASDAQ: LEGN) today announced preliminary results for the first half of 2020.

9 months ago - Business Wire

“Johnson & Johnson has deep roots in China with an innovation footprint dating back nearly four decades,” Chief Science Officer Paul Stoffels said last year.

11 months ago - Forbes

Pandemic-driven enthusiasm for biotech made this a great time for its initial public offering.

11 months ago - The Motley Fool

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates tar... [Read more...]

Industry
Biotechnology
IPO Date
Jun 5, 2020
Stock Exchange
NASDAQ
Ticker Symbol
LEGN
Full Company Profile

Financial Performance

In 2020, Legend Biotech's revenue was $75.68 million, an increase of 32.15% compared to the previous year's $57.26 million. Losses were -$303.48 million, 128.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Legend Biotech stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 57.96% from the latest price.

Price Target
$49.00
(57.96% upside)
Analyst Consensus: Buy